- Home
- ZYME vs LILAK Comparison
ZYME vs LILAK Comparison
Compare ZYME & LILAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZYME | LILAK |
|---|---|---|
| Founded | 2003 | 2017 |
| Country | United States | Bermuda |
| Employees | N/A | 9000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Cable & Other Pay Television Services |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | ZYME | LILAK |
|---|---|---|
| Price | $22.81 | $7.43 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 1 |
| Target Price | ★ $38.90 | $8.20 |
| AVG Volume (30 Days) | 531.8K | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $105,965,000.00 | N/A |
| Revenue This Year | $183.10 | $1.37 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 38.87 | N/A |
| 52 Week Low | $11.86 | $4.75 |
| 52 Week High | $29.75 | $9.13 |
Technical Indicators
Market Signals| Indicator | ZYME | LILAK |
|---|---|---|
| Relative Strength Index (RSI) | 36.89 | 52.20 |
| Support Level | $22.20 | $7.44 |
| Resistance Level | $23.66 | $7.62 |
| Average True Range (ATR) | 0.92 | 0.26 |
| MACD | -0.30 | 0.02 |
| Stochastic Oscillator | 1.07 | 58.06 |
Price Performance
Historical ComparisonAbout ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About LILAK Liberty Latin America Ltd. Class C
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.